{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Melanoma&page=3", "query": { "condition": "Metastatic Melanoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1219, "total_pages": 122, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Melanoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Melanoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T01:27:33.664Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00577382", "title": "SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucosal Lentiginous Melanoma", "Acral Lentiginous Malignant Melanoma" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2007-08", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2016-12-08", "last_synced_at": "2026-10-05T01:27:33.664Z", "location_count": 5, "location_summary": "Boston, Massachusetts • St Louis, Missouri • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577382" }, { "nct_id": "NCT03472586", "title": "Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Neoplasm in the Liver", "Metastatic Uveal Melanoma", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Embolization Therapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2018-05-02", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-05T01:27:33.664Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03472586" }, { "nct_id": "NCT06199713", "title": "Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma", "Melanoma Stage III", "Melanoma Stage IV", "Unresectable Melanoma" ], "interventions": [ { "name": "18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-01-30", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-10-05T01:27:33.664Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06199713" }, { "nct_id": "NCT00295958", "title": "LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Non-melanomatous Skin Cancer" ], "interventions": [ { "name": "LMB-2 immunotoxin", "type": "BIOLOGICAL" }, { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2005-12", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2012-06-14", "last_synced_at": "2026-10-05T01:27:33.664Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295958" }, { "nct_id": "NCT01258855", "title": "Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Recurrent Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Ziv-Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 84, "start_date": "2011-01-18", "completion_date": "2018-03-29", "has_results": true, "last_update_posted_date": "2019-05-10", "last_synced_at": "2026-10-05T01:27:33.664Z", "location_count": 21, "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01258855" }, { "nct_id": "NCT00003091", "title": "High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Melanoma (Skin)" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Hoag Memorial Hospital Presbyterian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1996-01", "completion_date": "2000-01", "has_results": false, "last_update_posted_date": "2011-05-12", "last_synced_at": "2026-10-05T01:27:33.664Z", "location_count": 4, "location_summary": "Newport Beach, California • Bloomington, Indiana • Knoxville, Tennessee + 1 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Knoxville", "state": "Tennessee" }, { "city": "Bryan", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003091" }, { "nct_id": "NCT00304525", "title": "A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "RAF265", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2006-04", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-05T01:27:33.664Z", "location_count": 10, "location_summary": "Aurora, Colorado • Augusta, Georgia • Baltimore, Maryland + 5 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00304525" }, { "nct_id": "NCT02038218", "title": "Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Brain Tumors", "Metastatic Malignant Neoplasm to Brain" ], "interventions": [ { "name": "4-Demethyl-4-cholestryloxycarbonylpenclomedine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DEKK-TEC, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2013-09", "completion_date": "2020-08", "has_results": true, "last_update_posted_date": "2020-09-16", "last_synced_at": "2026-10-05T01:27:33.664Z", "location_count": 3, "location_summary": "New Orleans, Louisiana • Lansing, Michigan • Houston, Texas", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Lansing", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02038218" }, { "nct_id": "NCT04990726", "title": "Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Melanoma, Stage II", "Melanoma Stage IV" ], "interventions": [ { "name": "Assessment", "type": "BEHAVIORAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2019-12-05", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-05T01:27:33.664Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990726" }, { "nct_id": "NCT05573035", "title": "A Study to Investigate LYL845 in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LYL845", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lyell Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 39, "start_date": "2022-12-19", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-10-05T01:27:33.664Z", "location_count": 18, "location_summary": "Sacramento, California • Santa Monica, California • Stanford, California + 14 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05573035" } ] }